Vaccination against human cancers (review)

Area of Science:

• Immunology
• Oncology
• Vaccinology

Background:

• Active tumor-specific immunization has been explored for decades using various vaccine types.
• Previous approaches included whole cell vaccines and tumor cell lysates.
• Recent advancements involve dendritic cell-based and genetically engineered vaccines.

Purpose of the Study:

• To review the historical and current landscape of active tumor-specific immunization strategies for human cancers.
• To highlight the mechanisms and outcomes of different vaccine types, including whole cell, dendritic cell, and genetically engineered vaccines.
• To emphasize the importance of understanding tumor immunoevasion for successful cancer immunotherapy.

Main Methods:

• Review of classical and molecular immunology studies on cancer vaccines.
• Analysis of vaccine preparations: whole cell, tumor lysate, dendritic cell-peptide, and genetically engineered tumor cells.
• Examination of immune responses (antibody, T cell) and clinical outcomes (relapse rates, remissions).

Main Results:

• Whole cell vaccines demonstrated preventive value by reducing relapse rates.
• Dendritic cell-peptide and genetically engineered vaccines showed potential for inducing remissions in metastatic disease.
• Generated immune reactions correlate with clinical response but are not always guaranteed.
• Successful immunization requires overcoming tumor immunoevasive strategies.

Conclusions:

• Active tumor-specific immunization, particularly with dendritic cell-peptide vaccines, offers promise for cancer treatment.
• Breaking host tolerance to tumors through appropriate antigen presentation is crucial.
• Further understanding of tumor-cell immunoevasion mechanisms is essential for developing more effective cancer vaccines and immunotherapies.